For healthcare providers especially pharmacists, nurses and physicians, we work to provide current information on drug updates, changes in the marketplace, and hot topics in the pharmacy industry.
Episode 86 - Tzield, Rezvoglar, & Kineret
A few updates for you this week, first the FDA approved Tzield to delay the progression of type 1 diabetes - a big advancement for the treatment of type 1 diabetes. The FDA also approved another biosimilar to Lantus, called Rezvoglar and issued a new EUA for Kineret for COVID-19 treatment. Don’t forget to like, share, & subscribe! ENJOY!
Episode 85 - Xylazine & "The Tripledemic"
Just two updates for you this week, first a review of the current situation regarding what the media has labeled as the “tripledemic” and a warning issued by the FDA related to certain illicit medications being laced with other sedatives. Don’t forget to like, share, & subscribe! ENJOY!
Episode 84 - Tecvayli & Imjudo
Two updates from the FDA this week, approvals for both Tecvayli for multiple myeloma and Imjudo for liver cancer. Don’t forget to like, share, & subscribe! ENJOY!
Episode 83 - COVID EUAs & amphetamine shortage
Two updates that I saw from the FDA this week, an updated EUA for the Pfizer and Moderna Bivalent COVID19 Vaccines, and a statement from the FDA on the current shortage of amphetamine salts. Don’t forget to like, share, & subscribe! ENJOY!
Episode 82 - Boostrix & Evusheld
Just two quick updates from the FDA this week, a new indication for Boostrix and updated Facts Sheet for Evusheld after some not so promising results with the new Omicron variant. Don’t forget to like, share, & subscribe! ENJOY!
Episode 81 - Nyquil chicken, Skysona, & Relyvrio
So we have a few things to review this week - first the FDA issuing a warning against some odd and potentially dangerous social media challenges which have been coming up. And then we have approval or updates from 3 products - Skysona, Retevmo, & Relyvrio. Don’t forget to like, share, & subscribe! ENJOY!
These Podcasts are invaluable. I love how you cut to the chase both on the clinical data and the economic impact. Keep up the great work!!!